
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics Inc is experiencing significant growth in operating expenses, reflecting an increase of 36% to $468 million in FY25 compared to FY24, indicating substantial investment in its clinical pipeline. The positive data from z-rostudirsen, demonstrating a statistically significant improvement in muscle content-adjusted dystrophin expression and long-term cardiopulmonary function, reinforces the company’s strong positioning for potential FDA accelerated approval. The pipeline's focus on commercially attractive indications and the anticipated positive trial readout from a competitor suggest further upside potential for Dyne Therapeutics, bolstering a favorable outlook for the stock.
Bears say
Dyne Therapeutics reported a significant net loss of $446 million for the year, equating to an earnings per share (EPS) of ($3.47), which is a slight increase in losses compared to the previous year. The company's challenging outlook is compounded by a series of potential downsides, including concerns over the efficacy of its lead candidate DYNE-101, slower-than-expected clinical trial progress, and potential safety issues with its drug delivery system. Additionally, Dyne's market capitalization of approximately $3 billion reflects investor apprehensions regarding the timeline and viability of its key programs, particularly in the competitive landscape of oligonucleotide therapies.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares